Lincoln Pharmaceuticals Limited Share Price & Analysis
₹558.10+1.46%Updated 28 Oct 2026, 03:30 pm IST
LTP
₹558.10+1.46%Open
₹541.10High
₹560.00Low
₹533.10Close
₹558.1052W High
₹770.0052W Low
₹440.00Volume
47KLot Size
1Sector
HealthcareMarket Cap
₹1K CrFace Value
₹10Small Cap
Price Chart
Candle
Range
Fundamentals
P/E
12.10Sector P/E
50.20P/B
1.65EPS
₹43.89ROE
12.30%ROCE
16.30%D/E Ratio
0.00Div Yield
0.31%Book Value
₹378.00Strengths
- Efficient capital deployment (ROCE 16.3%)
- Attractively valued vs sector (P/E 12.1x vs industry 50.2x)
- Virtually debt-free
Concerns
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
LINCOLN · as of Mar 2026
Promoters49.78%
FII5.00%0.16pp
Public45.23%0.16pp
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 49.81% | 49.54% | 49.78% | 49.78% | 49.78% | 49.78% |
| FII | 3.22% | 3.93% | 3.95% | 5.19% | 5.16% | 5.00% |
| DII | 0.06% | 0.05% | 0.04% | — | — | — |
| Public | 46.92% | 46.49% | 46.24% | 45.04% | 45.07% | 45.23% |
Corporate Events
Dividend - Rs 1.80 Per Share
Dividend11 Sept 2025
Dividend - Rs 1.80 Per Share
Dividend12 Sept 2024
Annual General Meeting/Dividend - Rs 1.50 Per Share
Dividend14 Sept 2023
Latest News
All newsLincoln Pharma sees leadership change in management
*Lincoln Pharma sees leadership change in management.* The company has announced a change in its management team, as disclosed in a regulatory filing. Such shifts may influence strategic direction and investor sentiment. 📊 *STOCKS:* $LINCPHARM | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #ManagementChange
NSE Filing24 Sept
Lincoln Pharma sees key management change
*Lincoln Pharma sees key management change.* The company announced a shift in its leadership structure as per a recent NSE filing. While specific details of the change were not disclosed, such moves can influence investor sentiment. **No financial figures** or strategic shifts were shared at this time. 📊 *STOCKS:* LINCPHARM | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #ManagementChange
NSE Filing24 Sept
Lincoln Pharma reports Q1 FY27 results
*Lincoln Pharma reports Q1 FY27 results* — The company has submitted its financial results for the quarter ended June 30, 2026. Key figures including revenue and net profit will be analyzed for performance trends. Results are in line with expectations, with no major deviations reported. 📊 *STOCKS:* $LINCPHARM | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Earnings
NSE Filing13 Aug
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹166 Cr 1.8% | ₹163 Cr 5.8% | ₹154 Cr 8.3% | ₹168 Cr 14.3% | ₹147 Cr 8.7% | ₹161 Cr 9.5% | ₹147 Cr 3.5% | ₹142 Cr |
| Op. Profit | ₹24 Cr 4.0% | ₹25 Cr 4.2% | ₹24 Cr 11.1% | ₹27 Cr 12.5% | ₹24 Cr 14.3% | ₹28 Cr 21.7% | ₹23 Cr 27.8% | ₹18 Cr |
| OPM | 14.0% 12.5% | 16.0% 6.7% | 15.0% 6.3% | 16.0% 0.0% | 16.0% 11.1% | 18.0% 20.0% | 15.0% 15.4% | 13.0% |
| Net Profit | ₹29 Cr 45.0% | ₹20 Cr 28.6% | ₹28 Cr 133.3% | ₹12 Cr 42.9% | ₹21 Cr 19.2% | ₹26 Cr 8.3% | ₹24 Cr 26.3% | ₹19 Cr |
| EPS (₹) | 14.28 43.1% | 9.98 27.8% | 13.82 139.1% | 5.78 44.3% | 10.37 21.1% | 13.15 11.3% | 11.82 27.2% | 9.29 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹623 Cr 7.2% | ₹581 Cr 13.9% | ₹510 Cr 8.1% | ₹472 Cr 11.3% | ₹424 Cr 9.8% | ₹386 Cr 5.5% | ₹366 Cr 1.4% | ₹361 Cr 0.3% | ₹360 Cr |
| Expenses | ₹522 Cr 8.8% | ₹480 Cr 14.0% | ₹421 Cr 12.0% | ₹376 Cr 11.6% | ₹337 Cr 5.0% | ₹321 Cr 7.4% | ₹299 Cr 2.9% | ₹308 Cr 1.6% | ₹313 Cr |
| Op. Profit | ₹102 Cr 2.0% | ₹100 Cr 11.1% | ₹90 Cr 6.3% | ₹96 Cr 10.3% | ₹87 Cr 31.8% | ₹66 Cr 2.9% | ₹68 Cr 28.3% | ₹53 Cr 12.8% | ₹47 Cr |
| OPM | 16.0% 5.9% | 17.0% 5.6% | 18.0% 10.0% | 20.0% 4.8% | 21.0% 23.5% | 17.0% 5.6% | 18.0% 20.0% | 15.0% 15.4% | 13.0% |
| Other Income | ₹22 Cr 35.3% | ₹34 Cr 54.5% | ₹22 Cr 120.0% | ₹10 Cr 100.0% | ₹5 Cr 54.5% | ₹11 Cr 120.0% | ₹5 Cr 0.0% | ₹5 Cr 150.0% | ₹2 Cr |
| Interest | ₹2 Cr 100.0% | ₹1 Cr 50.0% | ₹2 Cr 100.0% | ₹1 Cr 50.0% | ₹2 Cr 0.0% | ₹2 Cr 50.0% | ₹4 Cr 20.0% | ₹5 Cr 28.6% | ₹7 Cr |
| Depreciation | ₹13 Cr 18.2% | ₹11 Cr 22.2% | ₹9 Cr 12.5% | ₹8 Cr 0.0% | ₹8 Cr 14.3% | ₹7 Cr 0.0% | ₹7 Cr 16.7% | ₹6 Cr 0.0% | ₹6 Cr |
| PBT | ₹109 Cr 10.7% | ₹122 Cr 22.0% | ₹100 Cr 4.2% | ₹96 Cr 14.3% | ₹84 Cr 25.4% | ₹67 Cr 8.1% | ₹62 Cr 34.8% | ₹46 Cr 24.3% | ₹37 Cr |
| Tax % | 25.0% 4.2% | 24.0% 11.1% | 27.0% 3.6% | 28.0% 7.7% | 26.0% 13.0% | 23.0% 4.5% | 22.0% 12.0% | 25.0% 0.0% | 25.0% |
| Net Profit | ₹82 Cr 11.8% | ₹93 Cr 27.4% | ₹73 Cr 5.8% | ₹69 Cr 11.3% | ₹62 Cr 21.6% | ₹51 Cr 4.1% | ₹49 Cr 40.0% | ₹35 Cr 25.0% | ₹28 Cr |
| EPS (₹) | 41.11 11.7% | 46.58 28.0% | 36.4 5.1% | 34.63 11.3% | 31.12 21.0% | 25.72 5.6% | 24.36 40.7% | 17.31 23.1% | 14.06 |
| Div Payout | 4.0% 0.0% | 4.0% 0.0% | 4.0% 0.0% | 4.0% 20.0% | 5.0% 16.7% | 6.0% 0.0% | 6.0% 33.3% | 9.0% 0.0% | 9.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||||
| Equity Capital | ₹20 Cr 0.0% | ₹20 Cr 0.0% | ₹20 Cr 0.0% | ₹20 Cr 0.0% | ₹20 Cr 0.0% | ₹20 Cr 0.0% | ₹20 Cr 0.0% | ₹20 Cr 0.0% | ₹20 Cr 0.0% | ₹20 Cr |
| Reserves | ₹696 Cr 6.7% | ₹652 Cr 13.8% | ₹573 Cr 18.9% | ₹482 Cr 16.7% | ₹413 Cr 19.4% | ₹346 Cr 18.1% | ₹293 Cr 17.7% | ₹249 Cr 22.1% | ₹204 Cr 18.6% | ₹172 Cr |
| Borrowings | ₹0 Cr | ₹0 Cr 100.0% | ₹1 Cr 50.0% | ₹2 Cr 0.0% | ₹2 Cr 100.0% | ₹1 Cr 80.0% | ₹5 Cr 85.3% | ₹34 Cr 44.3% | ₹61 Cr 4.7% | ₹64 Cr |
| Other Liabilities | ₹139 Cr 11.2% | ₹125 Cr 17.9% | ₹106 Cr 27.7% | ₹83 Cr 16.2% | ₹99 Cr 16.5% | ₹85 Cr 19.7% | ₹71 Cr 12.7% | ₹63 Cr 1.6% | ₹62 Cr 29.2% | ₹48 Cr |
| Total Liabilities | ₹855 Cr 7.3% | ₹797 Cr 13.9% | ₹700 Cr 19.3% | ₹587 Cr 9.9% | ₹534 Cr 18.1% | ₹452 Cr 16.2% | ₹389 Cr 6.3% | ₹366 Cr 5.5% | ₹347 Cr 13.8% | ₹305 Cr |
Assets | ||||||||||
| Fixed Assets | ₹185 Cr 1.6% | ₹182 Cr 1.7% | ₹179 Cr 18.5% | ₹151 Cr 14.4% | ₹132 Cr 18.9% | ₹111 Cr 9.8% | ₹123 Cr 1.7% | ₹121 Cr 3.4% | ₹117 Cr 13.6% | ₹103 Cr |
| CWIP | ₹3 Cr 25.0% | ₹4 Cr 33.3% | ₹3 Cr 57.1% | ₹7 Cr 56.3% | ₹16 Cr 700.0% | ₹2 Cr | ₹0 Cr 100.0% | ₹2 Cr | ₹0 Cr 100.0% | ₹7 Cr |
| Investments | ₹209 Cr 20.1% | ₹174 Cr 25.2% | ₹139 Cr 52.7% | ₹91 Cr 6.2% | ₹97 Cr 19.8% | ₹81 Cr 138.2% | ₹34 Cr 88.9% | ₹18 Cr 63.6% | ₹11 Cr 10.0% | ₹10 Cr |
| Other Assets | ₹458 Cr 4.8% | ₹437 Cr 15.3% | ₹379 Cr 11.8% | ₹339 Cr 16.9% | ₹290 Cr 12.0% | ₹259 Cr 11.6% | ₹232 Cr 3.1% | ₹225 Cr 2.7% | ₹219 Cr 17.7% | ₹186 Cr |
| Total Assets | ₹855 Cr 7.3% | ₹797 Cr 13.9% | ₹700 Cr 19.3% | ₹587 Cr 9.9% | ₹534 Cr 18.1% | ₹452 Cr 16.2% | ₹389 Cr 6.3% | ₹366 Cr 5.5% | ₹347 Cr 13.8% | ₹305 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹93 Cr 47.6% | ₹63 Cr 61.5% | ₹39 Cr 48.7% | ₹76 Cr 10.1% | ₹69 Cr 8.0% | ₹75 Cr 41.5% | ₹53 Cr 96.3% | ₹27 Cr 8.0% | ₹25 Cr 44.4% | ₹45 Cr |
| Investing CF | ₹-79 Cr 38.6% | ₹-57 Cr 54.1% | ₹-37 Cr 52.6% | ₹-78 Cr 21.9% | ₹-64 Cr 106.5% | ₹-31 Cr 72.2% | ₹-18 Cr 50.0% | ₹-12 Cr 52.0% | ₹-25 Cr 40.5% | ₹-42 Cr |
| Financing CF | ₹-6 Cr 20.0% | ₹-5 Cr 25.0% | ₹-4 Cr 33.3% | ₹-3 Cr 50.0% | ₹-6 Cr 84.2% | ₹-38 Cr 5.6% | ₹-36 Cr 227.3% | ₹-11 Cr | ₹0 Cr 100.0% | ₹-3 Cr |
| Net Cash Flow | ₹8 Cr 700.0% | ₹1 Cr 150.0% | ₹-2 Cr 50.0% | ₹-4 Cr 300.0% | ₹-1 Cr 114.3% | ₹7 Cr 800.0% | ₹-1 Cr 133.3% | ₹3 Cr | ₹0 Cr | ₹0 Cr |
| Free Cash Flow | ₹74 Cr 208.3% | ₹24 Cr 7.7% | ₹26 Cr 16.1% | ₹31 Cr 49.2% | ₹61 Cr 10.3% | ₹68 Cr 78.9% | ₹38 Cr 123.5% | ₹17 Cr 142.9% | ₹7 Cr 36.4% | ₹11 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 97d 4.9% | 102d 4.1% | 98d 8.9% | 90d 8.2% | 98d 2.1% | 96d 21.3% | 122d 9.9% | 111d 20.7% | 92d 26.0% | 73d |
| Inventory Days | 99d 2.0% | 101d 4.7% | 106d 12.4% | 121d 40.7% | 86d 9.5% | 95d 26.7% | 75d 12.8% | 86d 36.5% | 63d 75.0% | 36d |
| Days Payable | 106d 11.6% | 95d 23.4% | 77d 35.8% | 120d 14.3% | 105d 2.9% | 102d 10.9% | 92d 12.2% | 82d 51.9% | 54d 35.0% | 40d |
| Cash Conv. Cycle | 90d 16.7% | 108d 14.3% | 126d 38.5% | 91d 16.7% | 78d 11.4% | 88d 17.0% | 106d 7.8% | 115d 15.0% | 100d 42.9% | 70d |
| Working Capital Days | 116d 4.1% | 121d 0.0% | 121d 7.1% | 113d 5.0% | 119d 5.6% | 126d 11.5% | 113d 27.0% | 89d 29.0% | 69d 122.6% | 31d |
| ROCE | 17.0% 22.7% | 22.0% 0.0% | 22.0% 8.3% | 24.0% 4.0% | 25.0% 13.6% | 22.0% 4.3% | 23.0% 21.1% | 19.0% 0.0% | 19.0% 9.5% | 21.0% |
Source: Screener.in · Lower days = better efficiency
Related Analysis
Frequently Asked Questions
What is Lincoln Pharmaceuticals Limited share price today?
Lincoln Pharmaceuticals Limited (LINCOLN) is currently trading at ₹558.1 on NSE, up 1.46% as of the last market session. Prices update daily after market close on MarketNetra.
Is Lincoln Pharmaceuticals Limited available in F&O (Futures & Options)?
Yes, Lincoln Pharmaceuticals Limited (LINCOLN) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Lincoln Pharmaceuticals Limited 52-week high and low?
Lincoln Pharmaceuticals Limited's 52-week high is ₹770 and the 52-week low is ₹440. The current price of ₹558.1 is 27.5% below the 52W high.
What is Lincoln Pharmaceuticals Limited P/E ratio?
Lincoln Pharmaceuticals Limited's current P/E ratio is 12.1. This indicates the market is paying ₹12.1 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Lincoln Pharmaceuticals Limited options?
Lincoln Pharmaceuticals Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade LINCOLN options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.